82 related articles for article (PubMed ID: 19238653)
1. Pharmacodynamics and pharmacokinetics of the novel thrombopoietin mimetic peptide RWJ-800088 in humans.
Liem-Moolenaar M; Cerneus D; Molloy CJ; End D; Brown KH; de Kam ML; Cohen AF; van Hensbergen Y; Burggraaf J
Clin Pharmacol Ther; 2008 Oct; 84(4):481-7. PubMed ID: 19238653
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand.
Wang B; Nichol JL; Sullivan JT
Clin Pharmacol Ther; 2004 Dec; 76(6):628-38. PubMed ID: 15592334
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic and pharmacodynamic modeling of pegylated thrombopoietin mimetic peptide (PEG-TPOm) after single intravenous dose administration in healthy subjects.
Samtani MN; Perez-Ruixo JJ; Brown KH; Cerneus D; Molloy CJ
J Clin Pharmacol; 2009 Mar; 49(3):336-50. PubMed ID: 19246731
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and hematological effects of the PEGylated thrombopoietin peptide mimetic GW395058 in rats and monkeys after intravenous or subcutaneous administration.
de Serres M; Yeager RL; Dillberger JE; Lalonde G; Gardner GH; Rubens CA; Simkins AH; Sailstad JM; McNulty MJ; Woolley JL
Stem Cells; 1999; 17(6):316-26. PubMed ID: 10606160
[TBL] [Abstract][Full Text] [Related]
5. The pharmacokinetics and pharmacodynamics of GW395058, a peptide agonist of the thrombopoietin receptor, in the dog, a large-animal model of chemotherapy-induced thrombocytopenia.
Case BC; Hauck ML; Yeager RL; Simkins AH; de Serres M; Schmith VD; Dillberger JE; Page RL
Stem Cells; 2000; 18(5):360-5. PubMed ID: 11007920
[TBL] [Abstract][Full Text] [Related]
6. Recombinant human thrombopoietin (rhTPO) after autologous bone marrow transplantation: a phase I pharmacokinetic and pharmacodynamic study.
Wolff SN; Herzig R; Lynch J; Ericson SG; Greer JP; Stein R; Goodman S; Benyunes MC; Ashby M; Jones DV; Fay J
Bone Marrow Transplant; 2001 Feb; 27(3):261-8. PubMed ID: 11277173
[TBL] [Abstract][Full Text] [Related]
7. In vivo effects of pegylated recombinant human megakaryocyte growth and development factor on hematopoiesis in normal mice.
Kabaya K; Akahori H; Shibuya K; Nitta Y; Ida M; Kusaka M; Kato T; Miyazaki H
Stem Cells; 1996 Nov; 14(6):651-60. PubMed ID: 8948023
[TBL] [Abstract][Full Text] [Related]
8. Thrombopoietin mimetic agents in the management of immune thrombocytopenic purpura.
Newland A
Semin Hematol; 2007 Oct; 44(4 Suppl 5):S35-45. PubMed ID: 18096471
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of the new antiepileptic and CNS drug RWJ-333369 following single and multiple dosing to humans.
Yao C; Doose DR; Novak G; Bialer M
Epilepsia; 2006 Nov; 47(11):1822-9. PubMed ID: 17116021
[TBL] [Abstract][Full Text] [Related]
10. Oral V2 receptor antagonist (RWJ-351647) in patients with cirrhosis and ascites: a randomized, double-blind, placebo-controlled, single ascending dose study.
Thuluvath PJ; Maheshwari A; Wong F; Yoo HW; Schrier RW; Parikh C; Steare S; Korula J
Aliment Pharmacol Ther; 2006 Sep; 24(6):973-82. PubMed ID: 16948809
[TBL] [Abstract][Full Text] [Related]
11. Clinical pharmacokinetics, platelet response, and safety of eltrombopag at supratherapeutic doses of up to 200 mg once daily in healthy volunteers.
Matthys G; Park JW; McGuire S; Wire MB; Bowen C; Williams D; Jenkins J; Peng B
J Clin Pharmacol; 2011 Mar; 51(3):301-8. PubMed ID: 20418510
[TBL] [Abstract][Full Text] [Related]
12. [Clinical tolerance test of recombinant human thrombopoietin].
Zhao Y; Jiang J; Jiao L
Zhonghua Yi Xue Za Zhi; 2001 Dec; 81(24):1508-11. PubMed ID: 16200777
[TBL] [Abstract][Full Text] [Related]
13. Thrombopoietin stimulates myelodysplastic syndrome granulocyte-macrophage and erythroid progenitor proliferation.
Ferrajoli A; Talpaz M; Kurzrock R; Harris D; Van Q; Estey EH; Estrov Z
Leuk Lymphoma; 1998 Jul; 30(3-4):279-92. PubMed ID: 9713960
[TBL] [Abstract][Full Text] [Related]
14. The effect of a novel, small non-peptidyl molecule butyzamide on human thrombopoietin receptor and megakaryopoiesis.
Nogami W; Yoshida H; Koizumi K; Yamada H; Abe K; Arimura A; Yamane N; Takahashi K; Yamane A; Oda A; Tanaka Y; Takemoto H; Ohnishi Y; Ikeda Y; Miyakawa Y
Haematologica; 2008 Oct; 93(10):1495-504. PubMed ID: 18728031
[TBL] [Abstract][Full Text] [Related]
15. Population analysis of the pharmacokinetics and pharmacodynamics of RWJ-270201 (BCX-1812) in treating experimental influenza A and B virus in healthy volunteers.
Iyer GR; Liao S; Massarella J
AAPS PharmSci; 2002; 4(4):E22. PubMed ID: 12645994
[TBL] [Abstract][Full Text] [Related]
16. A phase I, single and fractionated, ascending-dose study evaluating the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of an erythropoietin mimetic antibody fusion protein (CNTO 528) in healthy male subjects.
Bouman-Thio E; Franson K; Miller B; Getsy J; Cohen A; Bai SA; Yohrling J; Frederick B; Marciniak S; Jiao Q; Jang H; Davis H; Burggraaf J
J Clin Pharmacol; 2008 Oct; 48(10):1197-207. PubMed ID: 18812609
[TBL] [Abstract][Full Text] [Related]
17. Serum thrombopoietin and erythropoietin levels in patients with acute promyelocytic leukaemia during all-trans retinoic acid treatment.
Kinjo K; Kizaki M; Takayama N; Michikawa N; Oda A; Okamoto S; Tahara T; Kato T; Miyazaki H; Ikeda Y
Br J Haematol; 1999 May; 105(2):382-7. PubMed ID: 10233408
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and pharmacodynamics of Ro 44-3888 after single ascending oral doses of sibrafiban, an oral platelet aggregation inhibitor, in healthy male volunteers.
Wittke B; Mackie IJ; Machin SJ; Timm U; Zell M; Goggin T
Br J Clin Pharmacol; 1999 May; 47(5):521-30. PubMed ID: 10336576
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamics and pharmacokinetics of AMG 531, a thrombopoiesis-stimulating peptibody, in healthy Japanese subjects: a randomized, placebo-controlled study.
Kumagai Y; Fujita T; Ozaki M; Sahashi K; Ohkura M; Ohtsu T; Arai Y; Sonehara Y; Nichol JL
J Clin Pharmacol; 2007 Dec; 47(12):1489-97. PubMed ID: 17925591
[TBL] [Abstract][Full Text] [Related]
20. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study.
Bussel JB; de Miguel PG; Despotovic JM; Grainger JD; Sevilla J; Blanchette VS; Krishnamurti L; Connor P; David M; Boayue KB; Matthews DC; Lambert MP; Marcello LM; Iyengar M; Chan GW; Chagin KD; Theodore D; Bailey CK; Bakshi KK
Lancet Haematol; 2015 Aug; 2(8):e315-25. PubMed ID: 26688484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
